Le Lézard
Classified in: Health, Covid-19 virus
Subjects: MAV, CFG

Media Advisory - Prime Minister's itinerary for Monday, April 6, 2020


OTTAWA, April 5, 2020 /CNW/ -

Note: All times local

 

Ottawa, Ontario



11:15 a.m.

The Prime Minister will address Canadians on the COVID-19 situation, and a media availability will follow.




Rideau Cottage


1 Sussex Drive




Notes for media:




  • Open coverage
  • Media are asked to arrive to the Princess Anne Entrance no later than 10:45 a.m. and to make their way to the P1 Gate once on the grounds.
  • Media wishing to cover the event must be accredited with the Parliamentary Press Gallery.
  • Journalists can dial in to listen and ask questions to the Prime Minister.
  • Participant dial-in numbers:
    Local: 613-960-7527
    Toll-free: 1-888-265-0903
    Pass code: 3418355#  

 

This document is also available at http://pm.gc.ca

SOURCE Prime Minister's Office


These press releases may also interest you

at 08:30
Assure Holdings Corp. (the "Company" or "Assure") , a provider of intraoperative neuromonitoring ("IONM") and remote neurology services, today announced that it closed the sale of certain assets of its IONM business to MPOWERHealth on March 26, 2024....

at 08:30
SweetWater Brewing Company ("SweetWater Brewing" or "SweetWater"), the largest craft brewer in the Southeast and a subsidiary of Tilray Brands, Inc. , announced today the release of its new Hammer Red Amber Ale, the latest collaboration beer as part...

at 08:25
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell...

at 08:16
Canadian health care providers now have access to clinical tools and resources they need to better support older adults experiencing...

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...



News published on and distributed by: